Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

/p>

"This year continues to be very eventful for DOR," stated Christopher J. Schaber, PhD, President and CEO of DOR. "With our new partnership with Sigma-Tau, we are working diligently towards the initiation of our confirmatory Phase 3 clinical trial of orBec((R)) in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. Once the clinical trial is initiated, we expect to receive a $1 million milestone payment from Sigma-Tau in accordance with our collaboration agreement."

DOR's Recent Highlights:

On August 4, 2009, DOR announced that the Office of Orphan Products Development of the FDA granted Orphan Drug Designation to Oral BDP (beclomethasone 17,21-dipropionate, or orBec(R)) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease.

On July 8, 2009, DOR announced that it received a European patent addressing its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral delivery of drugs.

On July 7, DOR announced the appointment of Christopher P. Schnittker, CPA, as its new Vice President of Administration and Controller.

On June 29, 2009, DOR announced the publication in Bone Marrow Transplantation of orBec(R) clinical pulmonary data by investigators at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

On June 9, 2009, DOR announced that it received European Medicines Evaluation Agency (EMEA) agreement on the design of its confirmatory Phase 3 clinical trial of orBec(R) in acute GI GVHD.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec((R)) (oral beclomethasone dipropionate or
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Sleep disturbances such as ... correlated with depression. According to a study published ... three quarters of depressed patients have insomnia symptoms, ... young depressed adults and 10% of older patients, ... huge distress, have a major impact on quality ...
(Date:7/18/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... operating officer and president, has resigned, effective July 31, ... consultant going forward on special projects. His resignation is ... this position since September 2013. On an interim basis, ... , who has been Neogen,s chief executive officer since ...
(Date:7/18/2014)... (PRWEB) July 18, 2014 Global ... with US offices in Cambridge, MA, announces the ... Assay and Software product that leverages the power ... the Illumina® MiSeq sequencing platform. The assay and ... Children’s Hospital of Philadelphia (CHOP) and will include ...
(Date:7/18/2014)... 2014 Provia Laboratories announces the addition ... Board. Dr. Vaught has worked in the field ... As one of the founding members of ISBER ... - in 1999, he served as its second president, ... In 2005, Dr. Vaught began working with the National ...
Breaking Biology Technology:Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 2Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 3
... NEW HAVEN, Conn., Aug. 5 Rib-X Pharmaceuticals, Inc. ... discovery, development and commercialization of novel antibiotics for the treatment ... 2 clinical trial of radezolid in the treatment of community-acquired ... double-blind study, radezolid was administered orally at three different doses: ...
... , SANTA MONICA, Calif., Aug. 5 Cord ... stem cell preservation company ( http://www.cordblood-america.com ) ... families nationwide and internationally, said today it has retired $2.53M of ... in February and March of 2007 respectively, between CBAI and the ...
... ... medical exposition of its kind. John Rizvi will deliver a presentation titled, "Preservation of ... , ... 5, 2009 -- On August 13, 2009 at 1:00 PM, attorney John Rizvi will deliver ...
Cached Biology Technology:Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 2Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 3Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 4Cord Blood America Retires $2.53M Obligation 2Cord Blood America Retires $2.53M Obligation 3Patent Attorney John Rizvi Speaks at FIME International Medical Expo 2
(Date:7/21/2014)... are reasons mammoths and mastodons could have been the ... from the University of Cincinnati, the famously fuzzy relatives ... it was trendy at the end of the ... an assistant professor of geology and anthropology, shows the ... were year-round residents and not nomadic migrants as previously ...
(Date:7/21/2014)... La. Dr. Mark DeCoster, the James E. ... Louisiana Tech University, will present as an invited ... at the Biopolis Research and Development Center in ... faculty member in Louisiana Tech,s Institute for Micromanufacturing, ... 2D and 3D cell and tissue models." ...
(Date:7/21/2014)... resistance, and cheating in science are among the ... and mycology experts in Montreal at the three ... July 27 to August 1, 2014. Some 2,000 ... at the 14th International Congress of Bacteriology and ... and Eukaryotic Microbiology, and the 16th International Congress ...
Breaking Biology News(10 mins):Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3Louisiana Tech University professor presents at International Bioprinting Congress 2Montreal hosts International Union of Microbiology Societies congresses 2
... research professor and professor emeritus at The University of ... the American Academy of Arts & Sciences (AAAS), along ... Earl Jones, U.S. Secretary of Defense Robert Gates and ... scientist who translates his discoveries into technology that helps ...
... New York Sea Grant (NYSG) announces the release of ... Populations in South Shore Bays of Long Island, NY, ... of five research projects funded through NYSG,s Hard Clam ... NOAA National Marine Fisheries Service, South Shore Estuary Reserve, ...
... In Maine, government scientists have figured out how to measure ... and the sun - all the while saving money, energy, ... this energy-efficient ingenuity was the need to help the National ... spring snowmelt. The problem was this: While the USGS ...
Cached Biology News:University of Texas at Austin engineer elected to American Academy of Arts and Sciences 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 3Sea Grant report synthesizes recent research on New York's clams 2Measuring snow with a bucket, a windmill, and the sun? 2
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Biology Products: